SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.316
EU - Europa 2.333
AS - Asia 1.440
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
SA - Sud America 7
Totale 9.123
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.282
IT - Italia 1.172
CN - Cina 627
SG - Singapore 421
PL - Polonia 255
DE - Germania 238
UA - Ucraina 190
TR - Turchia 162
GB - Regno Unito 122
FI - Finlandia 103
ID - Indonesia 93
SE - Svezia 84
CA - Canada 33
BE - Belgio 30
CZ - Repubblica Ceca 26
HK - Hong Kong 25
VN - Vietnam 24
NL - Olanda 23
IN - India 19
FR - Francia 17
IR - Iran 16
RO - Romania 15
DK - Danimarca 14
JP - Giappone 12
NO - Norvegia 12
EU - Europa 10
TW - Taiwan 10
IQ - Iraq 8
AU - Australia 7
BR - Brasile 6
CH - Svizzera 5
KR - Corea 5
LT - Lituania 5
PT - Portogallo 5
GE - Georgia 4
ET - Etiopia 3
GR - Grecia 3
IE - Irlanda 3
NG - Nigeria 3
PK - Pakistan 3
RU - Federazione Russa 3
AT - Austria 2
ES - Italia 2
IL - Israele 2
KE - Kenya 2
MY - Malesia 2
PH - Filippine 2
TH - Thailandia 2
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MX - Messico 1
PE - Perù 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 9.123
Salva come PNG Salva come JPEG
Città #
Chandler 570
Fairfield 504
Santa Clara 441
Woodbridge 441
Singapore 349
Ferrara 323
Ashburn 278
Ann Arbor 277
Houston 264
Warsaw 254
Wilmington 220
Jacksonville 215
Seattle 206
Cambridge 173
New York 125
Izmir 119
Princeton 118
Nanjing 101
Jakarta 91
Shanghai 90
Milan 89
Dearborn 88
Beijing 74
Bremen 62
Helsinki 60
Boardman 59
San Diego 45
Los Angeles 44
Redwood City 41
Rome 38
Nanchang 36
Falls Church 35
Bologna 34
Shenyang 32
Brussels 25
Florence 24
Toronto 24
Dong Ket 23
Falkenstein 23
London 23
Guangzhou 22
Hebei 21
Jiaxing 21
Auburn Hills 20
San Mateo 20
Brno 17
Jinan 17
Kunming 16
Changsha 15
Norwalk 15
Tianjin 14
Frankfurt am Main 13
Zhengzhou 13
Hangzhou 12
Hong Kong 12
Washington 12
Mountain View 11
Ningbo 11
Munich 10
Praia A Mare 10
Hefei 9
Monmouth Junction 9
Naples 9
Piemonte 9
Augusta 8
Des Moines 8
Duncan 8
Ferrara di Monte Baldo 8
Oslo 8
Baghdad 7
Bari 7
Hounslow 7
Verona 7
Andover 6
Arona 6
Chicago 6
Leawood 6
Orange 6
Ottawa 6
Redmond 6
Albissola Marina 5
Catania 5
Fuzhou 5
Haikou 5
Olomouc 5
Padova 5
Philadelphia 5
Rochester 5
Taipei 5
Addison 4
Amsterdam 4
Atlanta 4
Bangalore 4
Cagliari 4
Calderara di Reno 4
Calvisano 4
Casoria 4
Castelcovati 4
Civitanova Marche 4
Copenhagen 4
Totale 6.575
Salva come PNG Salva come JPEG
Nome #
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 286
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 284
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 228
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 200
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 190
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 175
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 168
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 162
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 157
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 154
Hard surface biocontrol in hospitals using microbial-based cleaning products 148
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 147
Chronic sleep deprivation markedly reduces coagulation factor VII expression 141
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 139
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 136
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 130
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 127
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 125
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 124
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 123
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 123
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 118
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 113
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 110
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 110
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 108
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 107
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 107
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 106
F9 genotype and PK hemophilia B international study (GEPKHIS) 104
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 103
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 101
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 100
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 99
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 99
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 99
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 97
null 94
null 93
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 85
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 85
null 84
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 82
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 81
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 81
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 78
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 77
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 74
null 73
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 73
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 73
null 71
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 70
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 69
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 67
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 65
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 64
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 64
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 63
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 62
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 62
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 62
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 61
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 61
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 60
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 59
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 59
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 59
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 58
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 57
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 57
null 56
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 55
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 54
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 53
Hemostasis gene expression of the internal jugular and saphenous veins 53
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 52
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 52
Translation termination codons in protein synthesis and disease 51
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 51
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 50
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 49
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 49
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 49
Next generation factor VIIa with enhanced half-life 48
null 45
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 45
null 44
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 43
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 43
Improved intracellular processing of protein variants as a personalised therapeutic approach for haemophilia 42
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 42
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 42
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 41
Academic Editor per la rivista PLoS One 41
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 40
Associate Editor per la rivista Frontiers in Genetics - sezione Genetic Disorders 37
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 36
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 35
Exploring base editing for the correction of nonsense mutations in hemophilia B 35
Totale 8.864
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.224
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 299
Totale 50.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020851 0 0 0 0 0 242 151 126 123 125 55 29
2020/20211.400 64 55 53 92 61 100 255 176 82 198 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/20251.348 102 78 302 108 394 364 0 0 0 0 0 0
Totale 9.487